Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-denali-therapeutics-maintains-35-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:36:20

Cantor Fitzgerald analyst Charles Duncan reiterates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and maintains $35 pr...

Core News & Articles
Newmark Advises On $5B JV Partnership Betw...
09/09/2024 15:36:05

The Partnership is Between Blue Owl, Chirisa Technology Parks and PowerHouse Data CentersNEW YORK, Sept. 9, 2024 /PRNewswire/ -...

cantor-fitzgerald-reiterates-overweight-on-celldex-therapeutics-maintains-67-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:34:56

Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 p...

dell-technologies-to-be-included-in-sp-500-whats-going-on-with-the-stock
Dell Technologies To Be Included In S&P 50...
09/09/2024 15:34:29

Dell Technologies shares are trading higher Monday after S&P Dow Jones Indices announced on Friday that Dell will be added ...

cantor-fitzgerald-reiterates-overweight-on-biomarin-pharmaceutical-maintains-110-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:32:45

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

texans-want-weed-decriminalized-majority-supports-easing-cannabis-penalties-recent-poll-shows
Texans Want Weed Decriminalized: Majority ...
09/09/2024 15:31:44

A recently conducted survey in Texas showed the support for marijuana decriminalization is growing statewide. The new Universit...

how-is-the-market-feeling-about-cheniere-energy
How Is The Market Feeling About Cheniere E...
09/09/2024 15:30:25

looking-into-trade-desks-recent-short-interest
Looking Into Trade Desk's Recent Short Int...
09/09/2024 15:30:19

if-you-invested-100-in-this-stock-10-years-ago-you-would-have-400-today
If You Invested $100 In This Stock 10 Year...
09/09/2024 15:30:18

entg---analyzing-entegriss-short-interest
(ENTG) - Analyzing Entegris's Short Interest
09/09/2024 15:30:14

if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-7100-today
If You Invested $1000 In This Stock 15 Yea...
09/09/2024 15:30:13

relay-therapeutics-advances-towards-pivotal-trial-as-it-shares-encouraging-breast-cancer-data-in-heavily-pretreated-patients
Relay Therapeutics Advances Towards Pivota...
09/09/2024 15:30:00

Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human...

citigroup-maintains-neutral-on-guidewire-software-raises-price-target-to-165
Citigroup Maintains Neutral on Guidewire S...
09/09/2024 15:29:10

Citigroup analyst Tyler Radke maintains Guidewire Software (NYSE:GWRE) with a Neutral and raises the price target from $123 ...

cantor-fitzgerald-reiterates-overweight-on-biogen-maintains-292-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:28:53

Cantor Fitzgerald analyst Eric Schmidt reiterates Biogen (NASDAQ:BIIB) with a Overweight and maintains $292 price target.

citigroup-maintains-buy-on-brp-lowers-price-target-to-75
Citigroup Maintains Buy on BRP, Lowers Pri...
09/09/2024 15:26:54

Citigroup analyst James Hardiman maintains BRP (NASDAQ:DOOO) with a Buy and lowers the price target from $80 to $75.

citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-19
Citigroup Maintains Buy on Summit Therapeu...
09/09/2024 15:25:03

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

cantor-fitzgerald-reiterates-overweight-on-bridgebio-pharma-maintains-70-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:24:13

Cantor Fitzgerald analyst Josh Schimmer reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and maintains $70 price ...

live-on-cnbc-abercrombie--fitch-ceo-fran-horowitz-discusses-consumer-demand-raises-revenue-growth-guidance-to-12-13-vs-10-prior-operating-margin-14-15-vs-14-prior-previously-announced
Live On CNBC, Abercrombie & Fitch CEO Fran...
09/09/2024 15:22:24

cantor-fitzgerald-reiterates-overweight-on-axsome-therapeutics-maintains-107-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:21:39

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $107 p...

cantor-fitzgerald-reiterates-overweight-on-aurinia-pharmaceuticals-maintains-10-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:19:13

Cantor Fitzgerald analyst Olivia Brayer reiterates Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight and maintains $10...

Securely connect your financial account with CORE using Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist